
New coverage highlights medication reviews for mental fog after 60, with practical questions for clinicians and a careful look at dementia evidence.

On November 3, 2026, an article on the content aggregator Newswav urged older adults with mental fog or memory concerns to review prescriptions, over-the-counter medicines and supplements with a doctor or pharmacist.
The Newswav article discusses both changes in day-to-day thinking and research on longer-term dementia associations. Its practical focus is the full regimen rather than a single familiar prescription. That includes products bought for sleep or allergies alongside medicines prescribed for other conditions.
According to the coverage, anticholinergic medicines block acetylcholine. This chemical messenger is involved in learning and memory. Examples include diphenhydramine in some older allergy or sleep products and oxybutynin in some bladder medicines.
Its summary of the American Geriatrics Society Beers Criteria says clinicians may avoid many strongly anticholinergic medicines in older adults when suitable alternatives exist. This places the question with the clinician: is the current medicine still the right fit for the person's needs?
Newswav reports that benzodiazepines can affect memory, attention, coordination and reaction time. It also describes drowsiness and confusion with opioids, including impaired concentration.
The coverage also discusses statins. It reports that FDA-approved labeling acknowledges rare reports of cognitive symptoms that were usually reversible. These reports belong in a discussion of both possible effects and the medicine's treatment benefits.
The immediate implication is a change in the conversation, not an automatic change in treatment. For someone noticing new or worsening mental fog, the coverage recommends bringing a complete list of prescriptions and other products to a doctor or pharmacist. Over-the-counter medicines and supplements should be included rather than left outside the discussion.
A prescription-only review would leave out two categories named in the coverage: over-the-counter medicines and supplements. The task is to bring those products into the same discussion, not to decide in advance that any one item must be responsible.
A clinical review on medication use in frail older people recommends looking at medicine changes and actual use. It also calls for comparing the timing of medicines with the timing of symptoms. A list provides a starting point; the pattern of use helps the clinician assess whether a medicine might be contributing.
The practical distinction is between a symptom to describe and a conclusion about its cause. During a review, drowsiness and impaired concentration can be discussed as specific concerns. A broad phrase such as mental fog may start the conversation, but the clinical review's focus on symptoms and timing gives the discussion a more useful direction.
That means the review is about more than identifying a drug that appears in a headline. It is also about whether the combination of products fits the person's current situation. Newswav's attention to sedating medicines used together supports looking at the regimen as a whole.
Questions supported by the coverage and clinical review include:
A useful outcome is a clearer explanation of why each concern does or does not warrant a change. The decision may involve weighing a medicine's benefits against possible side effects rather than treating either as the whole story.
Do not stop or reduce a prescribed medicine independently. Newswav specifically warns regular benzodiazepine users against stopping suddenly. The clinical review also calls for weighing withdrawal risks alongside benefits and adverse effects.
If a change is proposed, the prescriber or pharmacist should explain the plan and any tapering or monitoring involved. Those details are individual clinical decisions. FitBrainLab has further context on preparing for a medicine and memory discussion.
A symptom such as drowsiness is not the same finding as a long-term dementia association. The November coverage did not announce a new clinical guideline or establish that every medicine it mentioned causes lasting cognitive decline.
Newswav cites a 2015 observational study of more than 3,400 older adults. It reports a 54% higher relative dementia risk in the group with the highest cumulative exposure to strong anticholinergic medicines compared with nonusers.
That result is an association rather than proof of cause. It concerns accumulated exposure to a medicine group, not a prediction for a particular person. It should not be reassigned to diphenhydramine or another individual product without drug-specific evidence.
The clinical review describes a further evidence gap. Its account of a 2023 Cochrane review reports only three short trials totaling 299 participants. The evidence that reducing anticholinergic burden improved cognition was very uncertain.
These findings do not establish that medication review or deprescribing will prevent dementia or restore memory.
The publication date of the coverage is not the date of all the evidence behind it. The article revisits earlier research, while the clinical review summarizes short trials. Reading those pieces separately helps keep a recent headline from sounding like a newly established medical conclusion.
Persistent, progressive or otherwise concerning cognitive symptoms still call for qualified assessment. A medicine review is part of that process rather than a substitute for it. For background on diagnostic discussions, FitBrainLab explains how mild cognitive impairment is assessed.
At FitBrainLab, the value of this coverage lies in making a specific clinical question easier to ask without turning a medicine list into a forecast of dementia. A review brings possible side effects into the same conversation as treatment benefits. That is a more useful frame than dividing medicines into simple categories of good or bad.
For long-term cognitive health, the broader lesson is to connect changes in thinking with a careful account of everyday treatment. Adults over 60 deserve an explanation that takes their symptoms seriously and respects why their medicines were prescribed. The goal is a well-informed decision with a qualified clinician.
Taking a full medicine list to a clinician turns a worrying headline into a specific discussion, and FitBrainLab supplies the evidence context for that decision. Alarmist dementia headlines can turn uncertainty into fear; the publication addresses that confusion with accessible accounts of brain-aging evidence that respect older readers and state where knowledge is limited.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog